NEXT GENERATION INVESTMENT BANKING

Members network
Limited Mobile Version
Follow this company and never miss a research update
AZN

AstraZeneca

Market Cap 773,900.0M
Today
Day High
622.00
612
Day Low
610.00
Day Open
611.50
Prev Close
612.00
VWAP
613.9
Volume
361K
Turnover
221.810M
Top Broker
VWAP
610.5
Avg Volume
370K
Avg Turnover
225.990M
Top Brokers
ENS/AVA
VWAP
602.0
Avg Volume
381K
Avg Turnover
229.296M
Top Brokers
SHB/NRD
VWAP
601.9
Avg Volume
394K
Avg Turnover
237.322M
Top Brokers
SHB/NRD
52 week summary
Price Range
464.8
Last
622.5
Beta
N/A
Market Cap
773,900.0M
Total Return
32.5%
Trailing P/E
N/A
Div Yield
N/A%
Shares Outstanding
1,264.5M
Next Earnings Date
27 Jul
Stock Exchange
NASDAQ Stockholm
5 day chart Go to advanced chart

Identify and measure trend strength in stocks with our Momentum tool to identify potential entry and exit signals. The tool provides a set of the most simple but powerful indicators that identify whether a stock is under sell or buy pressure.


Relative Price Strength
Change 3 Months 7.1%
Change 12 Months 5.0%
Volume Trend
Average Volume 10 vs 60 Days -22.1%
Price VS
52 Week High -1.7%
50 Day Moving Average 3.2%
200 Day moving Average 12.4%

Add article markers

Compare AstraZeneca to

Prev Close 0 Change 0
High 0 Avg Daily Volume 0
Low 0 Avg Daily Turnover 0
  • Management
  • Pascal Soriot, CEO
  • Executive board
  • Leif Johansson, Chairman of the board
Source: Millistream
Major Owners Equity Votes
BlackRock, Inc. 8.0%
8.0%
Investor AB 4.1%
4.1%
Source: Millistream
  •  
  • Profitability
  • ROE
  • ROCE
  • ROIC
  • EBITDA margin
  • EBIT margin
  • Net margin
  • Per share data (SEK)
  • EPS
  • EPS adj
  • Dividend
  • Net debt
  • Total shares
  • Valuation
  • EV (SEKm)
  • P/E
  • P/E diluted
  • P/Sales
  • EV/Sales
  • EV/EBITDA
  • EV/EBIT
  • P/BV
  • Capital structure
  • Equity ratio
  • Debt/equity ratio
  • Net debt(SEKm)
  • Capital employed(SEKm)
  • Capital turnover rate
  • (SEKm)
  • Net sales
  • Total operating costs
  • EBITDA
  • Depreciation
  • Amortization
  • Impairment charges
  • EBIT
  • Share in profits
  • Net financial items
  • Exchange rate dif.
  • Pre-tax profit
  • Tax
  • Net earnings
  • (SEKm)
  • Assets
  • Current assets
  • Cash in banks
  • Receivables
  • Inventories
  • Other current assets
  • Current assets
  • Fixed assets
  • Tangible assets
  • Associated comp.
  • Investments
  • Goodwill
  • Cap. exp. for dev.
  • O intangible rights
  • O non-current assets
  • Total fixed assets
  • Deferred tax assets
  • Total (assets)
  • Liabilities
  • Current liabilities
  • Short-term debt
  • Accounts payable
  • O current liabilities
  • Current liabilities
  • Long-term debt
  • O long-term liabilities
  • Convertibles
  • Total Liabilities
  • Deferred tax liab
  • Provisions
  • Shareholders' equity
  • Minority interest (BS)
  • Minority & equity
  • Total liab & SE
  • (SEKm)
  • Net sales
  • Total operating costs
  • Depreciations total
  • EBIT
  • Taxes on EBIT
  • NOPLAT
  • Depreciation
  • Gross cash flow
  • Change in WC
  • Gross CAPEX
  • Free cash flow

Estimated Values is behind membership

To access members-only content, you must login or register an account.

Our membership is about gaining access to unique research and knowledge through our analysts and a network of peers. Be the first to get information about news and research in the Nordic life science and technology sectors and use our tools and education to reach your personal and professional goals in investing.

Sign up Login
Source: Redeye
Source: Redeye

Presentations, research interviews and videos from our events listed here.


Source: Redeye